Novo Nordisk To Slash GLP-1 Drug Prices By Up To 50% In US Starting 2027

Novo Nordisk (NYSE: NVO) announced plans to cut the list prices of these drugs by up to 50% in the U.S. starting in 2027, on Tuesday.

Eli Lilly launches new form of obesity drug Zepbound with a month’s worth of doses in one pen

Eli Lilly on Monday launched a new form of its blockbuster obesity drug, Zepbound, that offers a month's worth of doses in a ...

Eli Lilly slips as Novo to cut list prices for GLP-1 drugs

Eli Lilly (LLY) stock falls as rival Novo Nordisk (NVO) plans to cut Wegovy, Ozempic & Rybelsus U.S. list prices from Jan 1, ...
Pharmaceutical Commerce

Eli Lilly Launches Multi-Dose KwikPen for Zepbound

Consolidation of four doses may lower secondary packaging complexity and improve fill-finish throughput predictability, although Lilly has not quantified manufacturing efficiency gains. Multi-dose use ...

Eli Lilly’s New $299 Month-Long GLP‑1 Injector Shows Why It’s Winning the Weight‑Loss Race

Eli Lilly, the drugmaker behind weight-loss treatments Mounjaro and Zepbound, has rapidly overtaken former market leader Novo ...

Lilly to launch multi-dose weight-loss drug device in US

Eli Lilly said on Monday it received the U.S. Food and Drug Administration's approval to launch a four-dose KwikPen for its weight-loss drug Zepbound, delivering a full month of the treatment in a ...